secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001867096-23-000136
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Record Q3 revenue $48.3M (+63% YoY); tightens FY23 guidance to $160-165M
------------------------------------------------------------------------

- Total revenue $48.3M, up 63% YoY and 27% QoQ; product revenue $41.7M, up 41% YoY.
- Gvoke net revenue $17.7M (+30% YoY); 58k prescriptions, 31% retail TRx glucagon share.
- Recorlev net revenue $8.1M (+$5.6M vs prior year); patients on therapy up 203%.
- Cash, cash equivalents and short-term investments $66.0M; expects cash flow breakeven in Q4 2023.
- Tightened full-year 2023 revenue guidance from $155-165M to $160-165M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000136/0001867096-23-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000136/xers-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer